ST
CORT icon

Smithfield Trust’s Corcept Therapeutics CORT Stock Holding History

Smithfield Trust’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-145
Closed -$5K – 1084
2025
Q4 		$5K Hold
145
– – ﹤0.01% 977
2025
Q3 		$12K Hold
145
– – ﹤0.01% 831
2025
Q2 		$11K Sell
145
-3
-2% -$218 ﹤0.01% 842
2025
Q1 		$17K Buy
+148
New +$9.01K ﹤0.01% 757

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Smithfield Trust's CORT Position: Q1 2026 in Review

Smithfield Trust sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 145 shares — an estimated $5K sold.

Smithfield Trust first reported a position in CORT in Q1 2025 and held it in 4 quarters. The position peaked at $17K in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Smithfield Trust reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Smithfield Trust sold 145 Corcept Therapeutics shares in Q1 2026, an estimated $5K.
  • Smithfield Trust first reported a position in Corcept Therapeutics in Q1 2025 and held it in 4 quarters.
  • Smithfield Trust's Corcept Therapeutics position peaked at $17K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.